Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29866475

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Jul
First author
Moreau P

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Jul;19(7):856-858. doi: 10.1016/S1470-2045(18)30411-X.
    note
    Source null
    related pmid
    29866476
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Aug;19(8):e382. doi: 10.1016/S1470-2045(18)30492-3.
    note
    Source null
    related pmid
    30102231
    relationship
    Erratum in

Authors and identifiers

  1. name
    Moreau P
    type
    Author
  2. name
    Mateos MV
    type
    Author
  3. name
    Berenson JR
    type
    Author
  4. name
    Weisel K
    type
    Author
  5. name
    Lazzaro A
    type
    Author
  6. name
    Song K
    type
    Author
  7. name
    Dimopoulos MA
    type
    Author
  8. name
    Huang M
    type
    Author
  9. name
    Zahlten-Kumeli A
    type
    Author
  10. name
    Stewart AK
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Moreau P
    type
    Author
  2. name
    Mateos MV
    type
    Author
  3. name
    Berenson JR
    type
    Author
  4. name
    Weisel K
    type
    Author
  5. name
    Lazzaro A
    type
    Author
  6. name
    Song K
    type
    Author
  7. name
    Dimopoulos MA
    type
    Author
  8. name
    Huang M
    type
    Author
  9. name
    Zahlten-Kumeli A
    type
    Author
  10. name
    Stewart AK
    type
    Author
bibliography ids
  1. nci-bib-781bc3f03e3e55c5384dc549
book metadata
content sha256
d47a0e1d41aa0b54cd385dff5e8ecc78e5371f4848b891de04037452521c0bcc
document type
citation
dois
  1. 10.1016/S1470-2045(18)30354-1
electronic publication date
display
2018 Jun 1
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:29866475
immutable id
pubmed:29866475@d47a0e1d41aa0b54cd385dff5e8ecc78e5371f4848b891de04037452521c0bcc
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
953-964
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Jul;19(7):856-858. doi: 10.1016/S1470-2045(18)30411-X.
    note
    Source null
    related pmid
    29866476
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Aug;19(8):e382. doi: 10.1016/S1470-2045(18)30492-3.
    note
    Source null
    related pmid
    30102231
    relationship
    Erratum in
outcomes validated
false
pmid
29866475
provenance
batch id
c4c0356d060413f719c2
provider
NCBI PubMed ESummary
record sha256
f601a6908c9c00d1c05e22a52a6bb3fb957bd823239ac8f48c49cff023f8ba3d
response sha256
adeb6beaad718f060a94981fd9e96a2eaddc4f781839549cb3e53cba822117c0
retrieved at
2026-09-09T23:47:33.674758+00:00
publication date
display
2018 Jul
precision
month
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29866475/
title
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.

Preserved source evidence · Not medical advice